Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-ranging study of lutein supplementation in persons aged 60 years or older.
Rosenthal JM, Kim J, de Monasterio F, Thompson DJ, Bone RA, Landrum JT, de Moura FF, Khachik F, Chen H, Schleicher RL, Ferris FL 3rd, Chew EY. Rosenthal JM, et al. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5227-33. doi: 10.1167/iovs.05-1513. Invest Ophthalmol Vis Sci. 2006. PMID: 17122107 Clinical Trial.
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
Zonozi R, Cortazar FB, Jeyabalan A, Sauvage G, Nithagon P, Huizenga NR, Rosenthal JM, Sipilief A, Cosgrove K, Laliberte KA, Rhee EP, Pendergraft WF 3rd, Niles JL. Zonozi R, et al. Among authors: rosenthal jm. Ann Rheum Dis. 2024 Feb 15;83(3):351-359. doi: 10.1136/ard-2023-224489. Ann Rheum Dis. 2024. PMID: 38123922 Clinical Trial.
Prescription of Aminoglycosides in 23 French Neonatal Intensive Care Units.
Martin-Mons S, Gouyon B, Lorrain S, Abasse S, Alexandre C, Binson G, Brat R, Caeymaex L, Couringa Y, Desbruyeres C, Meglio MD, Escourrou G, Flamein F, Flechelles O, Girard O, Kermorvant-Duchemin E, Lapillonne A, Lafon C, Di Maio M, Mazeiras G, Mourdie J, Moussy-Durandy A, Pages AS, Ramful D, Razafimahefa H, Rosenthal JM, Iacobelli S, Gouyon JB. Martin-Mons S, et al. Among authors: rosenthal jm. Antibiotics (Basel). 2021 Nov 20;10(11):1422. doi: 10.3390/antibiotics10111422. Antibiotics (Basel). 2021. PMID: 34827360 Free PMC article.
43 results